3.4. Inhibition of Ribonucleotide Reductase Reduces ER+ Palbociclib-Resistant Tumor Growth and Decreases NF-κB Activation, Whereas Palbociclib Resistance Increases CCND1 and RRM2 Expression. Here, RRM2 is linked to neoplasm.